Brain

Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients Worldwide

Retrieved on: 
Thursday, October 12, 2023
Cancer, Research, CHI3L1, Brain, Therapy, IND, Disease, Person, Malaria, HBV, Canadian Tire money, Lung, Luber, Fibrosis, Patient, Pharmaceutical industry, Vaccine, Virus

Virion has begun enrolling a multi-national, first-in-humans study, “VRON-0200,” for the treatment of persons with chronic hepatitis B virus (HBV) infection, with the goal of providing a functional cure for a disease that affects over 300 million patients worldwide.

Key Points: 
  • Virion has begun enrolling a multi-national, first-in-humans study, “VRON-0200,” for the treatment of persons with chronic hepatitis B virus (HBV) infection, with the goal of providing a functional cure for a disease that affects over 300 million patients worldwide.
  • “We are pleased to be entering into this joint venture with Virion.
  • We are also excited to help support their oncology program, which is targeted for IND submission in the next 9 months.
  • We look forward to rolling up our sleeves together and bringing our novel therapeutics to patients worldwide!”

OMNIQ ANNOUNCES THE ADDITION OF IN CAR FACE DETECTION TO ITS AI MACHINE VISION COMPREHENSIVE SOLUTION

Retrieved on: 
Thursday, October 12, 2023
Homeland security, Machine learning, Artificial neural network, Brain, VRS, Machine vision, Safety, Crime, SALT, Terror, Artificial intelligence, Airport, SAN, Medical device

SALT LAKE CITY, Oct. 12, 2023 (GLOBE NEWSWIRE) -- OMNIQ Corp. (NASDAQ: OMQS) (“OMNIQ” or “the Company”), a provider of Artificial Intelligence (AI)-based solutions, today announced it added in car face detection to its Machine Vision features and following a series of competitive tests by a demanding security authority has been selected to deploy its system with the new critical feature. OMNIQ was invited to demonstrate the new system for border control in North America.

Key Points: 
  • omniQ’s AI uses patented Neural Network algorithms that imitate the human brain for pattern recognition enabling smart and quick decision-making.
  • With this additional feature, we are offering a comprehensive solution that is found superior and more accurate than competitors.
  • OmniQ’s AI-based machine vision VRS solution uses patented Neural Network algorithms that imitate human brains for pattern recognition enabling smart and quick decision-making.
  • More than 20,000 omniQ AI-based machine vision sensors are installed worldwide, including approximately 8,000 in the U.S. omniQ’s AI based Machine vision capabilities are founded on patented features including vehicle identification by make and color combined with superior accuracy based on sophisticated algorithm and machine learning.

Guerbet: CHMP positive opinion

Retrieved on: 
Thursday, October 12, 2023
III, European, European Commission, Committee for Medicinal Products for Human Use, CHMP, Radiology, Agent handling, Brain, Breast, Pancreas, Medicine, Central nervous system, Liver, Magnetic resonance imaging, European Medicines Agency, Spine, EMA, FDA, Kidney, Committee, Lung, Human, MRI, Tissue, Civil service commission, CNS, Prostate, Gadolinium, Patient, Regulatory affairs, Medical imaging, Health, EU

Approved by the FDA in September 2022, Elucirem™ is produced in France and in the USA.

Key Points: 
  • Approved by the FDA in September 2022, Elucirem™ is produced in France and in the USA.
  • Villepinte, France, 12 october 2023: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion concerning the granting of a marketing authorisation for Elucirem™ (Gadopiclenol) in the European Union (EU) for use in adults and children aged 2 years and over for MRI with contrast enhancement.
  • The positive opinion from the CHMP is essentially based on data from two phase III clinical trials completed in March 2021.
  • "This positive opinion from the CHMP,
    at the end of 2023, will bring European patients and health professionals

Cerevel Therapeutics Announces Proposed Public Offering of Common Stock

Retrieved on: 
Wednesday, October 11, 2023
COVID-19, Telephone, Brain, Attention, Prospectus, Goldman Sachs, Biotechnology, FDA, Clinical trial, Suite, Security (finance), Patient, Sale, Montgomery Street, Incorporated, Stifel

In connection with this offering, Cerevel expects to grant the underwriters a 30-day option to purchase up to an additional $60.0 million of shares of its common stock at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • In connection with this offering, Cerevel expects to grant the underwriters a 30-day option to purchase up to an additional $60.0 million of shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • All shares to be sold in the proposed offering of common stock will be offered by Cerevel.
  • The offering of common stock will be made only by means of a prospectus supplement and accompanying prospectus.
  • Forward-looking statements in this press release include, but are not limited to, statements about: the terms of the proposed public offering of common stock, including our expectations with respect to granting the underwriters of the offering a 30-day option to purchase additional shares; and the completion, timing and size of the proposed public offering of common stock.

AI Robotics Company Electric Sheep Acquires Phenix Landscape and Complete Landscaping

Retrieved on: 
Wednesday, October 11, 2023
Language, Knowledge, Brain, Completeness, Murty, AI, Electric Sheep, LWM, Artificial intelligence, Entrepreneurship, Robotics, Growth, Maintenance, Marketing, SAN, Map, Phenix, Electricity, Heavy equipment

SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Electric Sheep, who is creating the first large-scale outdoor maintenance company powered by artificial intelligence and robotics, announced today two key acquisitions of landscaping businesses - Phenix Landscape and Complete Landscaping.

Key Points: 
  • SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Electric Sheep, who is creating the first large-scale outdoor maintenance company powered by artificial intelligence and robotics, announced today two key acquisitions of landscaping businesses - Phenix Landscape and Complete Landscaping.
  • Electric Sheep is an outdoor maintenance company powered by artificial intelligence and robotics.
  • What Open AI did with language, Electric Sheep wants to do for outdoor robotics - under the aircover of a profitable business model,” adds Murty.
  • “As part of Electric Sheep our customers are going to directly benefit from its proprietary AI robots that streamline time-consuming tasks like mowing.”
    “We are excited to join the Electric Sheep team and our customers are thrilled to be working with such a forward-thinking company utilizing AI technology to improve operations and efficiency,” said Derek Schendel of Phenix Landscaping.

UPDATE: Brain & Behavior Research Foundation Awards 2023 Outstanding Achievement Prizes to Five Leading Psychiatric Researchers

Retrieved on: 
Tuesday, October 10, 2023
Neuroscience, Long Shadow, Brain & Behavior Research Foundation, Bipolar disorder, Behavior, Causes, Person, Mental health, Obesity, Mental, DSM-IV codes, Research, Nursing, Vaccine, Brain

New York, Oct. 10, 2023 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation , the world’s largest private funder of mental health research grants, today announced it is awarding the 2023 Outstanding Achievement Prizes in Mental Health to five scientists for their exceptional work in advancing psychiatric research.

Key Points: 
  • New York, Oct. 10, 2023 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation , the world’s largest private funder of mental health research grants, today announced it is awarding the 2023 Outstanding Achievement Prizes in Mental Health to five scientists for their exceptional work in advancing psychiatric research.
  • The prizewinners will be the featured speakers at the BBRF International Mental Health Research Symposium on October 27, 2023, in New York City, and will receive their awards later that evening at the BBRF International Awards Dinner .
  • “We applaud the Outstanding Achievement Prizewinners for their extraordinary contributions to advancing the development of new treatments, cures, and methods of prevention for mental illness,” said Jeffrey Borenstein, M.D., President & CEO of the Brain & Behavior Research Foundation.
  • “Because of the groundbreaking work of the Outstanding Achievement Prizewinners, we are making great progress in our understanding of the brain and how to treat and potentially cure psychiatric illnesses,” said Herbert Pardes., M.D., President of the Brain & Behavior Research Foundation’s Scientific Council.

Brain & Behavior Research Foundation Awards 2023 Outstanding Achievement Prizes to Five Leading Psychiatric Researchers

Retrieved on: 
Tuesday, October 10, 2023
Neuroscience, Long Shadow, Brain & Behavior Research Foundation, Bipolar disorder, Behavior, Causes, Person, Mental health, Obesity, Mental, DSM-IV codes, Research, Nursing, Vaccine, Brain

New York, Oct. 10, 2023 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation , the world’s largest private funder of mental health research grants, today announced it is awarding the 2023 Outstanding Achievement Prizes in Mental Health to five scientists for their exceptional work in advancing psychiatric research.

Key Points: 
  • New York, Oct. 10, 2023 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation , the world’s largest private funder of mental health research grants, today announced it is awarding the 2023 Outstanding Achievement Prizes in Mental Health to five scientists for their exceptional work in advancing psychiatric research.
  • The prizewinners will be the featured speakers at the BBRF International Mental Health Research Symposium on October 27, 2023, in New York City, and will receive their awards later that evening at the BBRF International Awards Dinner .
  • “We applaud the Outstanding Achievement Prizewinners for their extraordinary contributions to advancing the development of new treatments, cures, and methods of prevention for mental illness,” said Jeffrey Borenstein, M.D., President & CEO of the Brain & Behavior Research Foundation.
  • “Because of the groundbreaking work of the Outstanding Achievement Prizewinners, we are making great progress in our understanding of the brain and how to treat and potentially cure psychiatric illnesses,” said Herbert Pardes., M.D., President of the Brain & Behavior Research Foundation’s Scientific Council.

NeuraSignal’s NovaGuide™ Intelligent Ultrasound System Significantly Outperforms Standard of Care for Detecting Stroke-Associated Heart Defects

Retrieved on: 
Tuesday, October 10, 2023
Patent, Diagnosis, Esophagus, PFO, Physician, Edward Hines, Acquisition, Intelligence, TCD, Brain, RLS, Risk, Heart, Safety, Travel, LOS, TEE, Recurrence, TTE, Principal, Robotics, Service, Neurology, Pathology, Veterans Health Administration, Patient, Medical imaging, Pharmaceutical industry, Stroke

LOS ANGELES, Oct. 10, 2023 (GLOBE NEWSWIRE) -- NeuraSignal, a medical technology and data company specializing in the assessment and management of brain health, today announced the publication of positive results from the BUBL clinical study (#NCT04604015) supporting the safety and superior performance of its NovaGuide Intelligent Ultrasound system in detecting Right to Left Shunt (RLS) — often due to a patent foramen ovale (PFO) — in patients with acute ischemic stroke. The data, published in Stroke, show that the NovaGuide system detected RLS that TTE missed. Importantly, NovaGuide also detected large RLS, which typically require intervention to prevent subsequent ischemic events, that were frequently missed with TTE.

Key Points: 
  • The data, published in Stroke , show that the NovaGuide system detected RLS that TTE missed.
  • Importantly, NovaGuide also detected large RLS, which typically require intervention to prevent subsequent ischemic events, that were frequently missed with TTE.
  • “An accurate assessment for RLS is a critical part of evaluating patients with cryptogenic ischemic stroke.
  • The standard of care for PFO screening is TTE, an ultrasound-based approach in which the ultrasound transducer is moved across the chest to create an image of the heart.

Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development

Retrieved on: 
Tuesday, October 10, 2023
DSM-IV codes, Asthma, Amgen, Neuropsychiatry, Research, Carbidopa, Brain, Therapy, L-DOPA, MDD, Migraine, Patient, Management, Fine chemical

WATERTOWN, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Robert Lenz, M.D., Ph.D., as executive vice president, head of research and development.

Key Points: 
  • WATERTOWN, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Robert Lenz, M.D., Ph.D., as executive vice president, head of research and development.
  • Dr. Lenz is a member of Neumora’s Executive Team reporting to Henry Gosebruch, chief executive officer.
  • “I am delighted to welcome Rob to the Neumora team.
  • “I am excited to join Neumora’s strong team of R&D leaders, and to leverage my expertise to advance our industry-leading pipeline of novel neuropsychiatry and neurodegeneration programs,” said Dr. Robert Lenz, executive vice president, head of research and development, Neumora.

Philips and World Stroke Organization partner to improve access to high-quality stroke care

Retrieved on: 
Tuesday, October 10, 2023
PHG, Partnership, NYSE, Google Images, Stroke, Death, Brain, Philips, Communication, Ambulance, Thrombectomy, Artificial intelligence, World Stroke Organization, Education, Rehabilitation, Policy, WSO, Disability, Life, Patient, AEX, Pharmaceutical industry

Two-year partnership focused on advocacy, education, and raising awareness of stroke as a global healthcare challenge

Key Points: 
  • Two-year partnership focused on advocacy, education, and raising awareness of stroke as a global healthcare challenge
    Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and the World Stroke Organization (WSO) , the world’s only global non-governmental organization focused on stroke, today announced the signing of a two-year partnership aimed at improving access to high-quality stroke care.
  • Announcing the partnership WSO President Prof Sheila Martins said, “WSO is committed to accelerating the global implementation of evidence-based treatment and care for stroke patients globally.
  • To improve access to high-quality care that reduces the burden stroke places on individuals, and the financial and social impact it has on society, Philips and WSO will collaborate across a range of stroke-related areas.
  • This quality-of-life-saving procedure is often performed to minimize damage to brain tissue and improve the chances of a patient's recovery after a stroke.